
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx Inc reported a significant increase in its operational capabilities, as evidenced by the growth in active implanting centers, which rose by 13 to reach a total of 240 at the end of the quarter. Despite a year-over-year increase of approximately 8% in total operating expenses to $25.8 million, the majority of this increment was attributed to rising selling, general, and administrative costs, which went up by around 11% to $23.4 million. The company's focus on expanding its global footprint in the United States market for its innovative Baroreflex Activation Therapy positions it favorably for future revenue growth amid growing demand for its neuromodulation solutions.
Bears say
CVRx has recently lowered its FY25 revenue guidance from a prior range of $55.0 - $58.0 million to a new range of $55.0 - $57.0 million, reflecting a subdued growth rate of approximately 7-11% year-over-year. The company also reduced its revenue estimate for 2026 from $74.1 million to $67.6 million, indicating expectations for a slower ramp-up in the U.S. market. Additionally, the gross margin remained flat at 84% for the second quarter of 2025, suggesting limited operational leverage and potential challenges in improving profitability.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares